Brian Park, PharmD

Brian Park, PharmD

Drug Information Specialist https://www.empr.com
Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

FDA Grants Accelerated Approval to Brukinsa for Mantle Cell Lymphoma

The Food and Drug Administration (FDA) has granted accelerated approval to Brukinsa (zanubrutinib; BeiGene USA) for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least 1 prior therapy. Zanubrutinib is a small molecule inhibitor of Bruton tyrosine kinase (BTK) that works by forming a covalent bond with a cysteine…

Eosinophil cells

Mepolizumab Reduces Flares in Patients With Hypereosinophilic Syndrome

GlaxoSmithKline announced positive results from the pivotal phase 3 study of mepolizumab in the treatment of patients with hypereosinophilic syndrome (HES). HES is a rare group of inflammatory disorders characterized by persistent eosinophilia that can potentially lead to inflammation, organ damage, and possibly death if left untreated.  The 32-week, double-blind, placebo-controlled phase 3 study evaluated…

Should Prescription Drugs Become OTC? Two Experts Weigh In

FDA: Dollar Tree Stores May Be Selling Potentially Harmful OTC Products

The Food and Drug Administration (FDA) has issued a warning letter to Greenbrier International for receiving over-the-counter (OTC) drugs produced by foreign manufacturers with multiple violations of current good manufacturing practices (CGMP). These contract manufacturers produced Dollar Tree’s Assured Brand OTC drugs, among other drug products sold at Dollar Tree and Family Dollar stores.  The…

Viloxazine NDA Submitted for Review as Potential New ADHD Treatment

The New Drug Application (NDA) for viloxazine hydrochloride (SPN-812; Supernus Pharmaceuticals), a serotonin norepinephrine modulating agent, has been submitted to the Food and Drug Administration (FDA) for the treatment of pediatric patients with attention deficit hyperactivity disorder (ADHD). The submission is supported by data from an extensive development program that included four phase 3 studies…

Olorofim Receives Breakthrough Therapy Designation for Invasive Fungal Infections

The Food and Drug Administration has granted Breakthrough Therapy designation to olorofim (formerly F901318; F2G) for the treatment of invasive mold infections in patients with limited or no treatment options, including aspergillosis refractory or intolerant to currently available therapy, and infections due to Lomentospora prolificans, Scedosporium, and Scopulariopsis species. Olorofim is part of a new…

Aztreonam + Avibactam Combo Therapy Granted QIDP, Fast Track Status for Antibiotic-Resistant Infections

The Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation and Fast Track designation to ATM-AVI (aztreonam and avibactam; Allergan) for the treatment of complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI), and hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP).  Aztreonam is a monobactam that has activity against metallo β-lactamase…